Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens

Ren-You Pan,Wen-Hung Chung,Mu-Tzu Chu,Shu-Jen Chen,Hua-Chien Chen,Lei Zheng,Shuen-Iu Hung

DOI: https://doi.org/10.1155/2018/4325874

IF: 4.4929

2018-12-19

Journal of Immunology Research

Abstract:Recently, increasing data show that immunotherapy could be a powerful weapon against cancers. Comparing to the traditional surgery, chemotherapy or radiotherapy, immunotherapy more specifically targets cancer cells, giving rise to the opportunities to the patients to have higher response rates and better quality of life and even to cure the disease. Cancer vaccines could be designed to target tumor-associated antigens (TAAs), cancer germline antigens, virus-associated antigens, or tumor-specific antigens (TSAs), which are also called neoantigens. The cancer vaccines could be cell-based (e.g., dendritic cell vaccine provenge (sipuleucel-T) targeting prostatic acid phosphatase for metastatic prostate cancer), peptide/protein-based, or gene- (DNA/RNA) based, with the different kinds of adjuvants. Neoantigens are tumor-specific and could be presented by MHC molecules and recognized by T lymphocytes, serving the ideal immune targets to increase the therapeutic specificity and decrease the risk of nonspecific autoimmunity. By targeting the shared antigens and private epitopes, the cancer vaccine has potential to treat the disease. Accordingly, personalized neoantigen-based immunotherapies are emerging. In this article, we review the literature and evidence of the advantage and application of cancer vaccine. We summarize the recent clinical trials of neoantigen cancer vaccines which were designed according to the patients’ personal mutanome. With the rapid development of personalized immunotherapy, it is believed that tumors could be efficiently controlled and become curable in the new era of precision medicine.

immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is immunotherapy in cancer treatment, especially the development and application of cancer vaccines targeting neoantigens. Specifically, the paper focuses on the following aspects:

1. **Improving the specificity of cancer treatment**: Traditional treatment methods such as surgery, chemotherapy or radiotherapy are often harmful to normal cells as well. However, immunotherapy, especially cancer vaccines targeting tumor - specific antigens (TSAs, namely neoantigens), can identify and attack cancer cells more accurately and reduce the impact on normal cells.

2. **Overcoming immune tolerance**: Neoantigens are generated by non - synonymous mutations, which do not exist in normal cells and are therefore not affected by central and peripheral tolerance mechanisms. This makes them ideal therapeutic targets, which can enhance the immune response and overcome the tolerance of the immune system to cancer cells.

3. **Reducing the risk of autoimmunity**: Since neoantigens only exist in cancer cells, using neoantigens as vaccine components can minimize the risk of autoimmune diseases caused by the immune response.

4. **Personalized treatment**: With the development of genome sequencing technology, personalized cancer vaccines can be designed according to the specific mutations of each patient's tumor. This personalized approach can improve the effectiveness and safety of treatment.

By reviewing the literature and summarizing the results of recent clinical trials, the paper explores the development potential of neoantigen - based cancer vaccines in the era of precision medicine, and how to achieve effective control and potential cure of cancer through these vaccines.